PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases.
Based on the Company’s core proprietary ‘Protein Interference’ technology, SITESEEKER® systematically unmasks cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of unmet diseases.
|Partner||Novartis, Plexxicon, Neophore, Sentinel Oncology, Vernalis, C4X Discovery|
|Investment Portfolio||Pre-Fund Investment|
|Co-Investors||Cambridge Enterprise. Parkwalk Advisors Amadeus Capital Partners Ltd. Morningside Group|
Jun 22 2018
Press Release – PhoreMost and o2h discovery collaborate to progress first-in-class drug discovery programs
Apr 26 2015
Investment in the seed round of Phoremost who have developed a next-generation phenotypic screening platform